CliffBio
small molecule

TRANEXAMIC ACID

TRANEXAMIC ACID

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameTRANEXAMIC ACID
Active ingredientTRANEXAMIC ACID
Strength100MG/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalMarch 2012
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.